Published in Biochim Biophys Acta on October 26, 2005
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods (2010) 1.71
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A (2007) 1.66
NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry (2012) 1.60
Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics (2010) 1.59
Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun (2015) 1.50
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells (2011) 1.48
Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc (2012) 1.44
Glycan labeling strategies and their use in identification and quantification. Anal Bioanal Chem (2010) 1.43
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol (2011) 1.30
Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem (2009) 1.22
Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics (2011) 1.20
Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. Biochemistry (2008) 1.17
Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. J Am Chem Soc (2011) 1.14
The impact of glycosylation on monoclonal antibody conformation and stability. MAbs (2011) 1.09
Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G. RNA (2008) 1.04
Function and 3D structure of the N-glycans on glycoproteins. Int J Mol Sci (2012) 1.04
Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem (2011) 0.99
Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. J Mol Biol (2012) 0.96
The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Structure (2015) 0.95
Recent advances in segmental isotope labeling of proteins: NMR applications to large proteins and glycoproteins. J Biomol NMR (2009) 0.95
The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor. MAbs (2016) 0.92
Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol (2014) 0.92
The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol (2008) 0.90
Determining the phagocytic activity of clinical antibody samples. J Vis Exp (2011) 0.87
Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding. Structure (2014) 0.86
Discovery and characterization of a peptide motif that specifically recognizes a non-native conformation of human IgG induced by acidic pH conditions. J Biol Chem (2009) 0.84
Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. PLoS One (2015) 0.83
Backbone (1)H, (13)C, and (15)N resonance assignments of the Fc fragment of human immunoglobulin G glycoprotein. Biomol NMR Assign (2014) 0.83
Consequences of glycan truncation on Fc structural integrity. MAbs (2014) 0.83
Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis. J Pharm Sci (2016) 0.83
A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry (2015) 0.80
Overexpression of a homogeneous oligosaccharide with 13C labeling by genetically engineered yeast strain. J Biomol NMR (2011) 0.79
Lanthanide binding and IgG affinity construct: potential applications in solution NMR, MRI, and luminescence microscopy. Protein Sci (2012) 0.79
Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors. PLoS One (2015) 0.77
NMR-based structural validation of therapeutic antibody produced in Nicotiana benthamiana. Plant Cell Rep (2015) 0.76
Transglycosylation Activity of Glycosynthase Mutants of Endo-β-N-Acetylglucosaminidase from Coprinopsis cinerea. PLoS One (2015) 0.76
Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering. Sci Rep (2017) 0.75
Stable isotope labeling of glycoprotein expressed in silkworms using immunoglobulin G as a test molecule. J Biomol NMR (2015) 0.75
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng (2004) 2.22
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep (2003) 2.01
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol (2007) 1.89
Defining the glycan destruction signal for endoplasmic reticulum-associated degradation. Mol Cell (2008) 1.86
Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A (2006) 1.78
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res (2004) 1.76
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology (2006) 1.69
Protein encapsulation within synthetic molecular hosts. Nat Commun (2012) 1.63
Crystal structure of UbcH5b~ubiquitin intermediate: insight into the formation of the self-assembled E2~Ub conjugates. Structure (2010) 1.63
Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol (2004) 1.59
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells (2011) 1.48
Human OS-9, a lectin required for glycoprotein endoplasmic reticulum-associated degradation, recognizes mannose-trimmed N-glycans. J Biol Chem (2009) 1.47
Crystal structure of a chaperone complex that contributes to the assembly of yeast 20S proteasomes. Nat Struct Mol Biol (2008) 1.45
Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1. Mol Cell Proteomics (2009) 1.45
Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res (2004) 1.41
Combinatorial protein display for the cell-based screening of biomaterials that direct neural stem cell differentiation. Biomaterials (2006) 1.40
Direct interactions between NEDD8 and ubiquitin E2 conjugating enzymes upregulate cullin-based E3 ligase activity. Nat Struct Mol Biol (2007) 1.38
IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods (2005) 1.37
The quail and chicken intestine have sialyl-galactose sugar chains responsible for the binding of influenza A viruses to human type receptors. Glycobiology (2007) 1.37
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res (2008) 1.36
Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res (2006) 1.34
Engineered therapeutic antibodies with improved effector functions. Cancer Sci (2009) 1.29
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther (2006) 1.28
Dissecting beta-ring assembly pathway of the mammalian 20S proteasome. EMBO J (2008) 1.28
IgEb immune complexes activate macrophages through FcgammaRIV binding. Nat Immunol (2007) 1.27
Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res (2005) 1.25
Structural basis for recognition of ubiquitinated cargo by Tom1-GAT domain. FEBS Lett (2005) 1.24
Molecular basis of sugar recognition by the human L-type lectins ERGIC-53, VIPL, and VIP36. J Biol Chem (2007) 1.23
Abeta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta (2010) 1.21
De novo design of foldable proteins with smooth folding funnel: automated negative design and experimental verification. Structure (2003) 1.20
Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res (2010) 1.20
A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res (2007) 1.18
Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol (2007) 1.18
14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J (2005) 1.18
Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes (2005) 1.16
Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem (2004) 1.13
The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res (2004) 1.13
Structural basis of sugar-recognizing ubiquitin ligase. Nat Struct Mol Biol (2004) 1.11
EDEM1 accelerates the trimming of alpha1,2-linked mannose on the C branch of N-glycans. Glycobiology (2010) 1.10
Alterations in receptor-binding properties of swine influenza viruses of the H1 subtype after isolation in embryonated chicken eggs. J Gen Virol (2009) 1.08
Structural basis for specific recognition of Rpt1p, an ATPase subunit of 26 S proteasome, by proteasome-dedicated chaperone Hsm3p. J Biol Chem (2012) 1.08
The role of MRH domain-containing lectins in ERAD. Glycobiology (2010) 1.07
Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev (2006) 1.07
Ero1-α and PDIs constitute a hierarchical electron transfer network of endoplasmic reticulum oxidoreductases. J Cell Biol (2013) 1.07
Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng (2006) 1.05
Sugar-binding properties of VIP36, an intracellular animal lectin operating as a cargo receptor. J Biol Chem (2005) 1.05
Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid Redox Signal (2009) 1.04
Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G. RNA (2008) 1.04
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer (2009) 1.04
Layer-by-layer assembly of poly(ethyleneimine) and plasmid DNA onto transparent indium-tin oxide electrodes for temporally and spatially specific gene transfer. Langmuir (2005) 1.03
Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol (2009) 1.03
Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res (2004) 1.02
Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. Biochem Biophys Res Commun (2003) 1.02
A non-canonical UBA-UBL interaction forms the linear-ubiquitin-chain assembly complex. EMBO Rep (2012) 1.01
Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods (2005) 1.01
Redox-dependent domain rearrangement of protein disulfide isomerase coupled with exposure of its substrate-binding hydrophobic surface. J Mol Biol (2009) 1.01
Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2003) 1.01
Alpha1,3-fucosyltransferase IX (Fut9) determines Lewis X expression in brain. Glycobiology (2003) 1.00
Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng (2004) 1.00
Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol (2007) 1.00
The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract (2003) 1.00
Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett (2009) 1.00
Molecular and structural basis for N-glycan-dependent determination of glycoprotein fates in cells. Biochim Biophys Acta (2012) 0.99
Sugar-binding activity of the MRH domain in the ER alpha-glucosidase II beta subunit is important for efficient glucose trimming. Glycobiology (2009) 0.99
Lewis X-carrying N-glycans regulate the proliferation of mouse embryonic neural stem cells via the Notch signaling pathway. J Biol Chem (2012) 0.98
Management and prognosis of cysts developed on long-term follow-up after Gamma Knife radiosurgery for intracranial arteriovenous malformations. Surg Neurol (2007) 0.97
Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. Biochem Biophys Res Commun (2007) 0.97
Molecular mechanism of ubiquitin recognition by GGA3 GAT domain. Genes Cells (2005) 0.97
Spectroscopic Characterization of Intermolecular Interaction of Amyloid β Promoted on GM1 Micelles. Int J Alzheimers Dis (2010) 0.96
Micropatterned, self-assembled monolayers for fabrication of transfected cell microarrays. Biochim Biophys Acta (2004) 0.96
Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol (2007) 0.96
Solution structure and dynamics of Ufm1, a ubiquitin-fold modifier 1. Biochem Biophys Res Commun (2006) 0.95
Conformational dynamics of wild-type Lys-48-linked diubiquitin in solution. J Biol Chem (2011) 0.95
Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res (2005) 0.95
The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology (2008) 0.95
Apolipoprotein A-I induces translocation of cholesterol, phospholipid, and caveolin-1 to cytosol in rat astrocytes. J Biol Chem (2001) 0.94
Up-and-down topological mode of amyloid beta-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconj J (2009) 0.94
Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL. J Lipid Res (2004) 0.93
N-Glycan structures of squid rhodopsin. Eur J Biochem (2003) 0.93
Edible bird's nest extract inhibits influenza virus infection. Antiviral Res (2006) 0.93